Cargando…

Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

BACKGROUND: The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales: Amano, Takahiro, Iijima, Hideki, Shinzaki, Shinichiro, Tashiro, Taku, Iwatani, Shuko, Tani, Mizuki, Otake, Yuriko, Yoshihara, Takeo, Sugimoto, Aya, Egawa, Satoshi, Yamaguchi, Shinjiro, Kinoshita, Kazuo, Araki, Manabu, Hirao, Motohiro, Sakakibara, Yuko, Hiyama, Satoshi, Ogawa, Hiroyuki, Nagaike, Koji, Murata, Jun, Komori, Masato, Okuda, Yorihide, Kizu, Takashi, Tsujii, Yoshiki, Hayashi, Yoshito, Inoue, Takahiro, Takahashi, Hidekazu, Mizushima, Tsunekazu, Morii, Eiichi, Takehara, Tetsuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406832/
https://www.ncbi.nlm.nih.gov/pubmed/34465291
http://dx.doi.org/10.1186/s12885-021-08724-5
_version_ 1783746562034237440
author Amano, Takahiro
Iijima, Hideki
Shinzaki, Shinichiro
Tashiro, Taku
Iwatani, Shuko
Tani, Mizuki
Otake, Yuriko
Yoshihara, Takeo
Sugimoto, Aya
Egawa, Satoshi
Yamaguchi, Shinjiro
Kinoshita, Kazuo
Araki, Manabu
Hirao, Motohiro
Sakakibara, Yuko
Hiyama, Satoshi
Ogawa, Hiroyuki
Nagaike, Koji
Murata, Jun
Komori, Masato
Okuda, Yorihide
Kizu, Takashi
Tsujii, Yoshiki
Hayashi, Yoshito
Inoue, Takahiro
Takahashi, Hidekazu
Mizushima, Tsunekazu
Morii, Eiichi
Takehara, Tetsuo
author_facet Amano, Takahiro
Iijima, Hideki
Shinzaki, Shinichiro
Tashiro, Taku
Iwatani, Shuko
Tani, Mizuki
Otake, Yuriko
Yoshihara, Takeo
Sugimoto, Aya
Egawa, Satoshi
Yamaguchi, Shinjiro
Kinoshita, Kazuo
Araki, Manabu
Hirao, Motohiro
Sakakibara, Yuko
Hiyama, Satoshi
Ogawa, Hiroyuki
Nagaike, Koji
Murata, Jun
Komori, Masato
Okuda, Yorihide
Kizu, Takashi
Tsujii, Yoshiki
Hayashi, Yoshito
Inoue, Takahiro
Takahashi, Hidekazu
Mizushima, Tsunekazu
Morii, Eiichi
Takehara, Tetsuo
author_sort Amano, Takahiro
collection PubMed
description BACKGROUND: The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA. METHODS: This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins. RESULTS: A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30–0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. CONCLUSION: Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08724-5.
format Online
Article
Text
id pubmed-8406832
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-84068322021-08-31 Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma Amano, Takahiro Iijima, Hideki Shinzaki, Shinichiro Tashiro, Taku Iwatani, Shuko Tani, Mizuki Otake, Yuriko Yoshihara, Takeo Sugimoto, Aya Egawa, Satoshi Yamaguchi, Shinjiro Kinoshita, Kazuo Araki, Manabu Hirao, Motohiro Sakakibara, Yuko Hiyama, Satoshi Ogawa, Hiroyuki Nagaike, Koji Murata, Jun Komori, Masato Okuda, Yorihide Kizu, Takashi Tsujii, Yoshiki Hayashi, Yoshito Inoue, Takahiro Takahashi, Hidekazu Mizushima, Tsunekazu Morii, Eiichi Takehara, Tetsuo BMC Cancer Research BACKGROUND: The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA. METHODS: This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins. RESULTS: A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30–0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. CONCLUSION: Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-021-08724-5. BioMed Central 2021-08-31 /pmc/articles/PMC8406832/ /pubmed/34465291 http://dx.doi.org/10.1186/s12885-021-08724-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Amano, Takahiro
Iijima, Hideki
Shinzaki, Shinichiro
Tashiro, Taku
Iwatani, Shuko
Tani, Mizuki
Otake, Yuriko
Yoshihara, Takeo
Sugimoto, Aya
Egawa, Satoshi
Yamaguchi, Shinjiro
Kinoshita, Kazuo
Araki, Manabu
Hirao, Motohiro
Sakakibara, Yuko
Hiyama, Satoshi
Ogawa, Hiroyuki
Nagaike, Koji
Murata, Jun
Komori, Masato
Okuda, Yorihide
Kizu, Takashi
Tsujii, Yoshiki
Hayashi, Yoshito
Inoue, Takahiro
Takahashi, Hidekazu
Mizushima, Tsunekazu
Morii, Eiichi
Takehara, Tetsuo
Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
title Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
title_full Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
title_fullStr Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
title_full_unstemmed Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
title_short Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
title_sort vascular endothelial growth factor-a is an immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406832/
https://www.ncbi.nlm.nih.gov/pubmed/34465291
http://dx.doi.org/10.1186/s12885-021-08724-5
work_keys_str_mv AT amanotakahiro vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT iijimahideki vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT shinzakishinichiro vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT tashirotaku vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT iwatanishuko vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT tanimizuki vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT otakeyuriko vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT yoshiharatakeo vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT sugimotoaya vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT egawasatoshi vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT yamaguchishinjiro vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT kinoshitakazuo vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT arakimanabu vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT hiraomotohiro vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT sakakibarayuko vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT hiyamasatoshi vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT ogawahiroyuki vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT nagaikekoji vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT muratajun vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT komorimasato vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT okudayorihide vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT kizutakashi vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT tsujiiyoshiki vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT hayashiyoshito vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT inouetakahiro vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT takahashihidekazu vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT mizushimatsunekazu vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT moriieiichi vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma
AT takeharatetsuo vascularendothelialgrowthfactoraisanimmunohistochemicalbiomarkerfortheefficacyofbevacizumabcontainingchemotherapyforduodenalandjejunaladenocarcinoma